This article was originally published in The Gray Sheet
Private placement valued at $1 mil. is announced with Century Medical of Tokyo, Japan. The placement consisted of 249,337 shares of Encore common stock. The financing "serves the dual function of strengthening Encore's capital structure and forging an even stronger alliance between our two companies," Encore Chairman and CEO Nick Cindrich says. The two firms' existing distribution agreement for Encore orthopedic trauma products in Japan also has been extended through December 2005
You may also be interested in...ï»¿
Stephen Hahnâ€™s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response â€“ but how quickly might that change to blame?
Keeping Track: US FDA Okays BMSâ€™ Zeposia In MS, Nixes Lilly/BIâ€™s Empagliflozin For Type 1 Diabetes
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.